Sorafenib: Difference between revisions
David Canner (talk | contribs) New page: ===Pharmacokinetics=== {| class="wikitable" border="1" width="40%" style="text-align:center" |- ! colspan="6" align="center"| VEGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Tran... |
David Canner (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
! colspan="6" align="center"| VEGFR Inhibitor [[ | ! colspan="6" align="center"| VEGFR Inhibitor [[Pharmacokinetics]] <ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
Line 9: | Line 9: | ||
! [[Sorafenib]] (Nexavar) | ! [[Sorafenib]] (Nexavar) | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ||
! 8 | ! 8 | ||
! 8.3 | ! 8.3 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! 24.6 | ! 24.6 | ||
! 460 | ! 460 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
! Variable | ! Variable | ||
! 29-49 | ! 29-49 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) | ||
! 95 | ! 95 | ||
! 99 | ! 99 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
! 83 | ! 83 | ||
! 29 | ! 29 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! 1921 | ! 1921 | ||
! 11040 | ! 11040 |